利特昔替尼(Ritlecitinib)治疗斑秃多久有效果？

Usually, Ritlecitinib (Ritlecitinib) can be effective in treating alopecia areata for about 24 or 26 weeks, which means that new hair will grow, which can help patients restore 80% of their hair growth, improve their personal image, and increase their self-confidence.

About rituxitinib

It provides a new mode of action, rapid onset of action, and better safety than other JAK inhibitors. It can regulate the hair growth cycle and has anti-inflammatory effects, so the application of rituxitinib in hair loss diseases other than AA may be beneficial.

The effective time of ritexitinib in the treatment of alopecia areata

For most patients with alopecia areata who take ritexitinib, after 24 weeks of treatment, 23% of patients have scalp hair covering 80% or more, and new hair has grown after 24 weeks of treatment. Some patients may need about 26 weeks of treatment to see obvious effects

Ritlecitinib in the treatment of alopecia areata

Research purpose

To evaluate the efficacy and safety of the Janus kinase inhibitors ritelecitinib and brepocitinib in patients with alopecia areata (AA) with ≥50% scalp hair loss.

Research Methods

Patients were randomly assigned to once-daily rituxitinib, brepocitinib, or placebo. The rituxitinib, brepocitinib, and placebo groups included 48, 47, and 47 patients, respectively. The primary efficacy endpoint was the 24-week change from baseline in the Severity of Hair Loss Tool (SALT) score.

Results

At Week 24, the least squares mean difference in severity score change from baseline was 31.1 for ritexitinib versus 49.2 for brepocitinib. 50% of patients on ritixitinib, 64% of patients on brepocitinib, and 2% of patients on placebo achieved SALT30.

After 24 weeks of treatment, 49.2% of patients achieved "moderate" to "extreme" improvement in alopecia areata, compared with only 9.2% in the placebo group. Treatment with ritixitinib or brepocitinib for 24 weeks was effective and well tolerated.

In another international multi-center, randomized, double-blind trial, 718 patients with alopecia areata over 12 years old who had at least 50% scalp hair loss were randomly assigned to take 30 mg or 50 mg of ritixitinib, 10 mg of ritixitinib, or placebo once daily.

Study data analysis showed that 23% of patients who received 50 mg of rituxitinib had scalp hair coverage of 80% or more (SALT≤20) after 6 months, compared with only 1.6% of the placebo group. The efficacy and safety of ritexitinib are consistent in adolescents and adults.

Safety

Ritexitinib is well tolerated in adult and adolescent patients, with the most common symptoms being diarrhea, acne, upper respiratory tract infection, urticaria, rash, folliculitis, dizziness, etc. At the same time, Pfizer is also evaluating the safety and efficacy of Ritlecitinib in an open-label, long-term Phase III ALLEGRO-LT study in adult patients with alopecia areata with a hair loss rate of ≥25% and in adolescent patients with alopecia areata aged 12 years and older with a hair loss rate of ≥50%.

Usage and Dosage

The recommended dose is 50mg, taken once a day, with or without food.

References:

King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. PMID: 33757798.

Related hot article recommendations: